Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FDA Extends Review of Eribulin NDA: Eisai
September 13, 2010
- Expand Range of Indications for Palivizumab: Dr Watabe
September 13, 2010
- Working Groups Created to Assess 8 Vaccines
September 13, 2010
- SRSM Created to Promote Regulatory Sciences
September 13, 2010
- Appeal Trial Begins on Online Sale of Classes 1, 2 OTC Drugs
September 13, 2010
- Addition of New Indications Unlikely to Make Any Drugs Eligible for Re-Pricing
September 13, 2010
- Sawai, Medisa to Recall Generics for Bromocriptine
September 13, 2010
- Orencia to Boost BMKK's Sales
September 13, 2010
- Nippon Kayaku Applies for Hycamtin Based on Data from Public Domain
September 13, 2010
- Nippon Chemiphar to Terminate Alliance with Nihon Chouzai
September 13, 2010
- Takeda Licenses Contrave from Orexigen
September 13, 2010
- 2010 ESC Congress Held in Stockholm
September 13, 2010
- Ono Licenses Salirasib from Concordia
September 13, 2010
- BI Applies for Dabigatran for SPAF in Japan
September 13, 2010
- ViiV Starts Full-Scale Operations in HIV Area in Japan
September 13, 2010
- Daiichi Sankyo Confident About Differentiation of Edoxaban
September 13, 2010
- Novartis Enhances Supply of Scientific Information
September 13, 2010
- Eisai's PAR-1 Antagonist Appears Promising as New Drug for Atherothrombosis
September 13, 2010
- Takeda Licenses Cell Culture-Based Flu Vaccine Technology from Baxter
September 13, 2010
- Astellas Confirms YM150's Safety for AF in PIIa in Japan/Asia
September 13, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…